secwatch.observer — SEC 8-K summary
======================================

Issuer:     ANGIODYNAMICS INC (ANGO)
CIK:        0001275187
Form:       8-K
Filed at:   2026-01-06T23:59:59+00:00
Accession:  0001140361-26-000341
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AngioDynamics Q2 beats; raises FY26 guidance; CEO Clemmer to retire; Med Tech growth +13%
--------------------------------------------------------------------------------

- Q2 net sales $79.4M (+8.8% YoY); Med Tech $35.7M (+13.0%); GAAP EPS -$0.15, adj. EPS $0.00.
- Raised FY26 net sales guidance to $312-314M (from $308-313M); Adj. EBITDA raised to $8-10M (from $6-10M).
- CEO Jim Clemmer to retire in FY2027; board initiates search; Q2 generated $4.7M cash, debt-free balance sheet.
- FDA IDE approvals for APEX-Return (AlphaVac blood management) and PAVE (AngioVac right-sided endocarditis) studies.
- Federal Circuit affirmed Bard patent invalidation, eliminating $3M contingent payment obligation from prior settlement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1275187/000114036126000341/0001140361-26-000341-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1275187/000114036126000341/ef20062354_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-26-000341

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer